Free tool
FAERS Monitor: Imuldosa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761364 or its brand name (Imuldosa, Ustekinumab-Srlf). Reports on generic versions are filed under their own applications.
Reports
2
Serious
2
100% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- colitis ulcerative1
- ear infection staphylococcal1
- ear pain1
- fatigue1
- groin abscess1
- hypoacusis1
- malaise1
- middle ear effusion1
- oral mucosal blistering1
- periodontitis1
- psoriasis1
- skin fissures1
- social problem1
- subcutaneous abscess1
- tinnitus1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,157 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ear infection staphylococcal | 1 | 87000.6 | 21511.3 | 21,571 |
| groin abscess | 1 | 8936.4 | 2232.3 | 2,231 |
| periodontitis | 1 | 4857.9 | 1214.1 | 1,213 |
| middle ear effusion | 1 | 4769.9 | 1192.2 | 1,191 |
| social problem | 1 | 2540.9 | 635.3 | 634 |
| subcutaneous abscess | 1 | 2194.5 | 548.7 | 548 |
| oral mucosal blistering | 1 | 1645.6 | 411.5 | 410 |
| ear pain | 1 | 541.1 | 135.3 | 134 |
| skin fissures | 1 | 538.2 | 134.6 | 134 |
| hypoacusis | 1 | 244.3 | 61.1 | 60 |
| colitis ulcerative | 1 | 235.3 | 58.8 | 58 |
| tinnitus | 1 | 228.9 | 57.3 | 56 |
| psoriasis | 1 | 80.5 | 20.1 | 19 |
| malaise | 1 | 24.0 | 6.0 | 5 |
| fatigue | 1 | 13.5 | 3.4 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.